Beyond oncolytic virotherapy: Replication-competent retrovirus vectors for selective and stable transduction of tumors

Current Gene Therapy

Volumn 5, Issue 6, 2005, Pages 655-667

  Dalba, Charlotte ^a   Klatzmann, David ^b   Logg, Christopher R ^c   Kasahara, Noriyuki ^c  

^a EPIXIS SA   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antineoplastic agents; Cancer; Gene therapy; Genetic vectors; Moloney murine leukemia virus; Neoplasms; Retroviridae; Virus replication

Indexed keywords

ADENOVIRUS VECTOR; ANTIRETROVIRUS AGENT; CANCER VACCINE; CYTOSINE DEAMINASE; FLUCYTOSINE; ONCOLYTIC VIRUS; ONYX 015; PRODRUG; RETROVIRUS VECTOR; VIRUS VACCINE; ZIDOVUDINE;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER THERAPY; CELL CULTURE; CELL KILLING; CLINICAL TRIAL; DRUG MEGADOSE; GENE TRANSFER; GLIOBLASTOMA; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; IN VIVO STUDY; INOCULATION; MURINE LEUKEMIA VIRUS; NONHUMAN; REVIEW; SUICIDE GENE; TRANSCRIPTION REGULATION; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS HYBRID; VIRUS REPLICATION; VIRUS TRANSMISSION;

DRUG DESIGN; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MODELS, BIOLOGICAL; MODELS, GENETIC; NEOPLASMS; ONCOLYTIC VIROTHERAPY; RETROVIRIDAE; RISK ASSESSMENT; TRANSDUCTION, GENETIC; VIRUS REPLICATION;

ADENOVIRIDAE; MOLONEY MURINE LEUKEMIA VIRUS; MURINE LEUKEMIA VIRUS; RETROVIRIDAE;

EID: 29444457742     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652305774964659     Document Type: Review

References (123)

1. Aboody, K.S., Brown, A., Rainov, N.G., Bower, K.A., Liu, S., Yang, W., Small, J.E., Herrlinger, U., Ourednik, V., Black, P.M., Breakefield, X.O. and Snyder, E.Y. (2000) Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc. Natl. Acad. Sci. USA, 97: 12846-51.
2. Andreansky, S., Soroceanu, L., Flotte, E.R., Chou, J., Marken, J.M., Gillespie, G.Y., Roizman, B. and Whitley, R.J. (1997) Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res., 57: 1502-9.
3. Andreansky, S.S., He, B., Gillespie, G.Y., Soroceanu, L., Markert, J., Chou, J., Roizman, B. and Whitley, R.J. (1996) The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc. Natl. Acad. Sci. USA, 93: 11313-8.
4. Au, G.G., Lindberg, A.M., Barry, R.D. and Shafren, D.R. (2005) Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21. Int. J. Oncol., 26: 1471-6.
5. Balachandran, S. and Barber, G.N. (2000) Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life, 50: 135-8.
6. Balachandran, S. and Barber, G.N. (2004) Defective translational control facilitates vesicular stomatitis virus oncolysis. Cancer Cell, 5: 51-65.
7. Balachandran, S., Porosnicu, M. and Barber, G.N. (2001) Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J. Virol., 75: 3474-9.
8. Barber, G.N. (2004) Vesicular stomatitis virus as an oncolytic vector. Viral Immunol., 17: 516-27.
9. Biermann, V., Volpers, C., Hussmann, S., Stock, A., Kewes, H., Schiedner, G., Herrmann, A. and Kochanek, S. (2001) Targeting of high-capacity adenoviral vectors. Hum. Gene Ther., 12: 1757-69.
10. Bischoff, J.R., Kirn, D.H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J.A., Sampson-Johannes, A., Fattaey, A. and McCormick, F. (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science, 274: 373-6.
11. Borovjagin, A.V., Krendelchtchikov, A., Ramesh, N., Yu, D.C., Douglas, J.T. and Curiel, D.T. (2005) Complex mosaicism is a novel approach to infectivity enhancement of adenovirus type 5-based vectors. Cancer Gene Ther., 12: 475-86.
12. Chang, Z., Pan, J., Logg, C., Kasahara, N. and Roy-Burman, P. (2001) A replication-competent feline leukemia virus, subgroup A (FeLV-A), tagged with green fluorescent protein reporter exhibits in vitro biological properties similar to those of the parental FeLV-A. J. Virol., 75: 8837-41.
13. Check, E. (2005) Gene therapy put on hold as third child develops cancer. Nature, 433: 561.
14. Cherry, S.R., Biniszkiewicz, D., van Parijs, L., Baltimore, D. and Jaenisch, R. (2000) Retroviral expression in embryonic stem cells and hematopoietic stem cells. Mol. Cell. Biol., 20: 7419-26.
15. Chikkanna-Gowda, C.P., Sheahan, B.J., Fleeton, M.N. and Atkins, G.J. (2005) Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12. Gene Ther., 12: 1253-63.
16. Chiocca, E.A., Abbed, K.M., Tatter, S., Louis, D.N., Hochberg, F.H., Barker, F., Kracher, J., Grossman, S.A., Fisher, J.D., Carson, K., Rosenblum, M., Mikkelsen, T., Olson, J., Markert, J., Rosenfeld, S., Nabors, L.B., Brem, S., Phuphanich, S., Freeman, S., Kaplan, R. and Zwiebel, J. (2004) A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol. Ther., 10: 958-66.
17. Chu, R.L., Post, D.E., Khuri, F.R. and Van Meir, E.G. (2004) Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin. Cancer Res., 10: 5299-312.
18. Coffey, M.C., Strong, J.E., Forsyth, P.A. and Lee, P.W. (1998) Reovirus therapy of tumors with activated Ras pathway. Science, 282: 1332-4.
19. Cornetta, K., Moen, R.C., Culver, K., Morgan, R.A., McLachlin, J.R., Sturm, S., Selegue, J., London, W., Blaese, R.M. and Anderson, W.F. (1990) Amphotropic murine leukemia retrovirus is not an acute pathogen for primates. Hum. Gene Ther., 1: 15-30.
20. Cornetta, K., Morgan, R.A., Gillio, A., Sturm, S., Baltrucki, L., O'Reilly, R. and Anderson, W.F. (1991) No retroviremia or pathology in long-term follow-up of monkeys exposed to a murine amphotropic retrovirus. Hum. Gene Ther., 2: 215-9.
21. Coukos, G., Makrigiannakis, A., Kang, E.H., Rubin, S.C., Albelda, S.M. and Molnar-Kimber, K.L. (2000) Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer [In Process Citation]. Clin. Cancer Res., 6: 3342-53.
22. Coulombe, J., Avis, Y. and Gray, D.A. (1996) A replication-competent promoter-trap retrovirus. J. Virol., 70: 6810-5.
23. Csatary, L.K., Eckhardt, S., Bukosza, I., Czegledi, F., Fenyvesi, C., Gergely, P., Bodey, B. and Csatary, C.M. (1993) Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect. Prev., 17: 619-27.
24. Csatary, L.K., Moss, R.W., Beuth, J., Torocsik, B., Szeberenyi, J. and Bakacs, T. (1999) Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H). Anticancer Res., 19: 635-8.
25. Culver, K.W., Ram, Z., Wallbridge, S., Ishii, H., Oldfield, E.H. and Blaese, R.M. (1992) In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science, 256: 1550-2.
26. Dewey, R.A., Morrissey, G., Cowsill, C.M., Stone, D., Bolognani, F., Dodd, N.J., Southgate, T.D., Klatzmann, D., Lassmann, H., Castro, M.G. and Lowenstein, P.R. (1999) Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. Nat. Med., 5: 1256-63.
27. Dillon, P.J., Lenz, J. and Rosen, C.A. (1991) Construction of a replication-competent murine retrovirus vector expressing the human immunodeficiency virus type 1 tat transactivator protein. J. Virol., 65: 4490-3.
28. Dock, G. (1904) Influence of complicating diseases upon leukaemia. J. Med. Sci., 127: 563-92.
29. Donahue, R.E., Kessler, S.W., Bodine, D., McDonagh, K., Dunbar, C., Goodman, S., Agricola, B., Byrne, E., Raffeld, M., Moen, R., Bacher, J., Zsebo, K.M. and Nienhuis, A.N. (1992) Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J. Exp. Med., 176: 1125-35.
30. Ebert, O., Shinozaki, K., Kournioti, C., Park, M.S., Garcia-Sastre, A. and Woo, S.L. (2004) Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. Cancer Res., 64: 3265-70.
31. Ehrlich, M. (2002) DNA methylation in cancer: too much, but also too little. Oncogene, 21: 5400-13.
32. Ellis, J. and Yao, S. (2005) Retrovirus silencing and vector design: relevance to normal and cancer stem cells? Curr. Gene Ther., 5: 367-73.
33. Fueyo, J., Gomez-Manzano, C., Alemany, R., Lee, P.S., McDonnell, T.J., Mitlianga, P., Shi, Y.X., Levin, V.A., Yung, W.K. and Kyritsis, A.P. (2000) A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene, 19: 2-12.
34. Galanis, E., Okuno, S.H., Nascimento, A.G., Lewis, B.D., Lee, R.A., Oliveira, A.M., Sloan, J.A., Atherton, P., Edmonson, J.H., Erlichman, C., Randlev, B., Wang, Q., Freeman, S. and Rubin, J. (2005) Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther., 12: 437-45.
35. Galanis, E., Vile, R. and Russell, S.J. (2001) Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors. Crit. Rev. Oncol. Hematol., 38: 177-92.
36. Gomella, L.G., Mastrangelo, M.J., McCue, P.A., Maguire, H.J., Mulholland, S.G. and Lattime, E.C. (2001) Phase i study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J. Urol., 166: 1291-5.
37. Gromeier, M., Lachmann, S., Rosenfeld, M.R., Gutin, P.H. and Wimmer, E. (2000) Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc. Natl. Acad. Sci. USA, 97: 6803-8.
38. Grote, D., Russell, S.J., Cornu, T.I., Cattaneo, R., Vile, R., Poland, G.A. and Fielding, A.K. (2001) Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood, 97: 3746-54.
39. Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M.P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C.S., Pawliuk, R., Morillon, E., Sorensen, R., Forster, A., Fraser, P., Cohen, J.I., de Saint Basile, G., Alexander, I., Wintergerst, U., Frebourg, T., Aurias, A., Stoppa-Lyonnet, D., Romana, S., Radford-Weiss, I., Gross, F., Valensi, F., Delabesse, E., Macintyre, E., Sigaux, F., Soulier, J., Leiva, L.E., Wissler, M., Prinz, C., Rabbitts, T.H., Le Deist, F., Fischer, A. and Cavazzana-Calvo, M. (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science, 302: 415-9.
40. Halene, S., Wang, L., Cooper, R.M., Bockstoce, D.C., Robbins, P.B. and Kohn, D.B. (1999) Improved expression in hematopoietic and lymphoid cells in mice after transplantation of bone marrow transduced with a modified retroviral vector. Blood, 94: 3349-57.
41. Hamid, O., Varterasian, M.L., Wadler, S., Hecht, J.R., Benson, A., 3rd, Galanis, E., Uprichard, M., Omer, C., Bycott, P., Hackman, R.C. and Shields, A.F. (2003) Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J. Clin. Oncol., 21: 1498-504.
42. Hazelrigg, M.R., Hirsch, J.I. and Merchant, R.E. (2002) Distribution of adoptively transferred, tumor-sensitized lymphocytes in the glioma-bearing rat. J. Neurooncol., 60: 143-50.
43. Hecht, J.R., Bedford, R., Abbruzzese, J.L., Lahoti, S., Reid, T.R., Soetikno, R.M., Kirn, D.H. and Freeman, S.M. (2003) A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin. Cancer Res., 9: 555-61.
44. Heise, C. and Kirn, D.H. (2000) Replication-selective adenoviruses as oncolytic agents. J. Clin. Invest., 105: 847-51.
45. Hirasawa, K., Nishikawa, S.G., Norman, K.L., Coffey, M.C., Thompson, B.G., Yoon, C.S., Waisman, D.M. and Lee, P.W. (2003) Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res., 63: 348-53.
46. Jaenisch, R. (1976) Germ line integration and Mendelian transmission of the exogenous Moloney leukemia virus. Proc. Natl. Acad. Sci. USA, 73: 1260-4.
47. Jespersen, T., Duch, M., Carrasco, M.L., Warming, S. and Pedersen, F.S. (1999) Expression of heterologous genes from an IRES translational cassette in replication competent murine leukemia virus vectors. Gene, 239: 227-35.
48. Kasuya, H., Takeda, S., Nomoto, S. and Nakao, A. (2005) The potential of oncolytic virus therapy for pancreatic cancer. Cancer Gene Ther., 12: 725-36.
49. Kempler, G., Freitag, B., Berwin, B., Nanassy, O. and Barklis, E. (1993) Characterization of the Moloney murine leukemia virus stem cell-specific repressor binding site. Virology, 193: 690-9.
50. Kirn, D.H. and McCormick, F. (1996) Replicating viruses as selective cancer therapeutics. Mol. Med. Today, 2: 519-27.
51. Kooby, D.A., Carew, J.F., Halterman, M.W., Mack, J.E., Bertino, J.R., Blumgart, L.H., Federoff, H.J. and Fong, Y. (1999) Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J., 13: 1325-34.
52. Kruse, C.A., Visonneau, S., Kleinschmidt-DeMasters, B.K., Gup, C.J., Gomez, G.G., Paul, D.B. and Santoli, D. (2000) The human leukemic T-cell line, TALL-104, is cytotoxic to human malignant brain tumors and traffics through brain tissue: implications for local adoptive immunotherapy. Cancer Res., 60: 5731-9.
53. Kuruppu, D. and Tanabe, K.K. (2005) Viral oncolysis by herpes simplex virus and other viruses. Cancer Biol. Ther., 4: 524-31.
54. Levaditi, C. and Nicolau, S. (1922) Affinite du virus herpetique pour les neoplasmes epitheliaux. Comptes Rendus Societe Biologie, 87: 498-500.
55. Li, Z., Dullmann, J., Schiedlmeier, B., Schmidt, M., von Kalle, C., Meyer, J., Forster, M., Stocking, C., Wahlers, A., Frank, O., Ostertag, W., Kuhlcke, K., Eckert, H.G., Fehse, B. and Baum, C. (2002) Murine leukemia induced by retroviral gene marking. Science, 296: 497.
56. Lin, E. and Nemunaitis, J. (2004) Oncolytic viral therapies. Cancer Gene Ther., 11: 643-64.
57. Logg, C.R., Logg, A., Matusik, R.J., Bochner, B.H. and Kasahara, N. (2002) Tissue-specific transcriptional targeting of a replication-competent retroviral vector. J. Virol., 76: 12783-91.
58. Logg, C.R., Logg, A., Tai, C.K., Cannon, P.M. and Kasahara, N. (2001a) Genomic stability of murine leukemia viruses containing insertions at the Env-3′ untranslated region boundary. J. Virol., 75: 6989-98.
59. Logg, C.R., Tai, C.K., Logg, A., Anderson, W.F. and Kasahara, N. (2001b) A uniquely stable replication-competent retrovirus vector achieves efficient gene delivery in vitro and in solid tumors. Hum. Gene Ther., 12: 921-32.
60. Lorence, R.M., Pecora, A.L., Major, P.P., Hotte, S.J., Laurie, S.A., Roberts, M.S., Groene, W.S. and Bamat, M.K. (2003) Overview of phase I studies of intravenous administration of PV701, an oncolytic virus. Curr. Opin. Mol. Ther., 5: 618-24.
61. Lorence, R.M., Rood, P.A. and Kelley, K.W. (1988) Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity. J. Natl. Cancer Inst., 80: 1305-12.
62. Lu, W., Zheng, S., Li, X.F., Huang, J.J., Zheng, X. and Li, Z. (2004) Intratumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial. World J. Gastroenterol., 10: 3634-8.
63. Mann, R., Mulligan, R.C. and Baltimore, D. (1983) Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell, 33: 153-9.
64. McCart, J.A., Ward, J.M., Lee, J., Hu, Y., Alexander, H.R., Libutti, S.K., Moss, B. and Bartlett, D.L. (2001) Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res., 61: 8751-7.
65. Modin, C., Lund, A.H., Schmitz, A., Duch, M. and Pedersen, F.S. (2000) Alleviation of murine leukemia virus repression in embryonic carcinoma cells by genetically engineered primer binding sites and artificial tRNA primers. Virology, 278: 368-79.
66. Molloy, S., Allcutt, D., Brennan, P., Farrell, M.A., Perryman, R. and Brett, F.M. (2000) Herpes simplex encephalitis occurring after chemotherapy, surgery, and stereotactic radiotherapy for medulloblastoma. Arch. Pathol. Lab. Med., 124: 1809-12.
67. Myers, R., Greiner, S., Harvey, M., Soeffker, D., Frenzke, M., Abraham, K., Shaw, A., Rozenblatt, S., Federspiel, M.J., Russell, S.J. and Peng, K.W. (2005) Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer. Cancer Gene Ther., 12: 593-9.
68. Nakamizo, A., Marini, F., Amano, T., Khan, A., Studeny, M., Gumin, J., Chen, J., Hentschel, S., Vecil, G., Dembinski, J., Andreeff, M. and Lang, F.F. (2005) Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res., 65: 3307-18.
69. Nemunaitis, J., Khuri, F., Ganly, I., Arseneau, J., Posner, M., Vokes, E., Kuhn, J., McCarty, T., Landers, S., Blackburn, A., Romel, L., Randlev, B., Kaye, S. and Kirn, D. (2001) Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol., 19: 289-98.
70. Nettelbeck, D.M. (2003) Virotherapeutics: conditionally replicative adenoviruses for viral oncolysis. Anticancer Drugs, 14: 577-84.
71. Norman, K.L., Hirasawa, K., Yang, A.D., Shields, M.A. and Lee, P.W. (2004) Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc. Natl. Acad. Sci. USA, 101: 11099-104.
72. Norman, K.L. and Lee, P.W. (2000) Reovirus as a novel oncolytic agent. J. Clin. Invest., 105: 1035-8.
73. Norman, K.L. and Lee, P.W. (2005) Not all viruses are bad guys: the case for reovirus in cancer therapy. Drug Discov. Today, 10: 847-55.
74. Ochiai, H., Moore, S.A., Archer, G.E., Okamura, T., Chewning, T.A., Marks, J.R., Sampson, J.H. and Gromeier, M. (2004) Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus. Clin. Cancer Res., 10: 4831-8.
75. Pecora, A.L., Rizvi, N., Cohen, G.I., Meropol, N.J., Sterman, D., Marshall, J.L., Goldberg, S., Gross, P., O'Neil, J.D., Groene, W.S., Roberts, M.S., Rabin, H., Bamat, M.K. and Lorence, R.M. (2002) Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J. Clin. Oncol., 20: 2251-66.
76. Peng, K.W., TenEyck, C.J., Galanis, E., Kalli, K.R., Hartmann, L.C. and Russell, S.J. (2002) Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res., 62: 4656-62.
77. Post, D.E., Fulci, G., Chiocca, E.A. and Van Meir, E.G. (2004) Replicative oncolytic herpes simplex viruses in combination cancer therapies. Curr. Gene Ther., 4: 41-51.
78. Rainov, N.G. (2000) A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther., 11: 2389-401.
79. Ram, Z., Culver, K.W., Walbridge, S., Blaese, R.M. and Oldfield, E.H. (1993) In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res., 53: 83-8.
80. Reid, T., Galanis, E., Abbruzzese, J., Sze, D., Wein, L.M., Andrews, J., Randlev, B., Heise, C., Uprichard, M., Hatfield, M., Rome, L., Rubin, J. and Kirn, D. (2002a) Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res., 62: 6070-9.
81. Reid, T., Warren, R. and Kirn, D. (2002b) Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther., 9: 979-86.
82. Reid, T.R., Freeman, S., Post, L., McCormick, F. and Sze, D.Y. (2005) Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther., 12: 673-81.
83. Reif, A.E. (1985) Vaccination of adult and newborn mice of a resistant strain (C57BL/6J) against challenge with leukemias induced by Moloney murine leukemia virus. Cancer Res., 45: 25-31.
84. Reik, W., Weiher, H. and Jaenisch, R. (1985) Replication-competent Moloney murine leukemia virus carrying a bacterial suppressor tRNA gene: selective cloning of proviral and flanking host sequences. Proc. Natl. Acad. Sci. USA, 82: 1141-5.
85. Ruprecht, R.M., Mullaney, S., Bernard, L.D., Gama Sosa, M.A., Hom, R.C. and Finberg, R.W. (1990) Vaccination with a live retrovirus: the nature of the protective immune response. Proc. Natl. Acad. Sci. USA, 87: 5558-62.
86. Russell, S.J. (1994) Replicating vectors for cancer therapy: a question of strategy. Semin. Cancer Biol., 5: 437-43.
87. Sanai, N., Tramontin, A.D., Quinones-Hinojosa, A., Barbaro, N.M., Gupta, N., Kunwar, S., Lawton, M.T., McDermott, M.W., Parsa, A.T., Manuel-Garcia Verdugo, J., Berger, M.S. and Alvarez-Buylla, A. (2004) Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration. Nature, 427: 740-4.
88. Shah, A.C., Benos, D., Gillespie, G.Y. and Markert, J.M. (2003) Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. J. Neurooncol., 65: 203-26.
89. Shah, K., Hsich, G. and Breakefield, X.O. (2004) Neural precursor cells and their role in neuro-oncology. Dev. Neurosci., 26: 118-30.
90. Shen, Y. and Nemunaitis, J. (2005) Fighting cancer with vaccinia virus: teaching new tricks to an old dog. Mol. Ther., 11: 180-95.
91. Short, M.P., Choi, B.C., Lee, J.K., Malick, A., Breakefield, X.O. and Martuza, R.L. (1990) Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line. J. Neurosci. Res., 27: 427-39.
92. Sinkovics, J.G. and Horvath, J.C. (2000) Newcastle disease virus (NDV): brief history of its oncolytic strains. J. Clin. Virol., 16: 1-15.
93. Sinn, P.L., Sauter, S.L. and McCray, P.B., Jr. (2005) Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors - design, biosafety, and production. Gene Ther., 12: 1089-98.
94. Soifer, H., Higo, C., Logg, C.R., Jih, L.J., Shichinohe, T., Harboe-Schmidt, E., Mitani, K. and Kasahara, N. (2002) A novel, helper-dependent, adenovirus-retrovirus hybrid vector: stable transduction by a two-stage mechanism. Mol. Ther., 5: 599-608.
95. Solly, S.K., Trajcevski, S., Frisen, C., Holzer, G.W., Nelson, E., Clerc, B., Abordo-Adesida, E., Castro, M., Lowenstein, P. and Klatzmann, D. (2003) Replicative retroviral vectors for cancer gene therapy. Cancer Gene Ther., 10: 30-9.
96. Stojdl, D.F., Lichty, B., Knowles, S., Marius, R., Atkins, H., Sonenberg, N. and Bell, J.C. (2000) Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med., 6: 821-5.
97. Stojdl, D.F., Lichty, B.D., tenOever, B.R., Paterson, J.M., Power, A.T., Knowles, S., Marius, R., Reynard, J., Poliquin, L., Atkins, H., Brown, E.G., Durbin, R.K., Durbin, J.E., Hiscott, J. and Bell, J.C. (2003) VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell, 4: 263-75.
98. Studeny, M., Marini, F.C., Dembinski, J.L., Zompetta, C., Cabreira-Hansen, M., Bekele, B.N., Champlin, R.E. and Andreeff, M. (2004) Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J. Natl. Cancer Inst., 96: 1593-603.
99. Stuhlmann, H., Jaenisch, R. and Mulligan, R.C. (1989) Transfer of a mutant dihydrofolate reductase gene into pre- and postimplantation mouse embryos by a replication-competent retrovirus vector. J. Virol., 63: 4857-65.
100. Swindle, C.S., Kim, H.G. and Klug, C.A. (2004) Mutation of CpGs in the murine stem cell virus retroviral vector long terminal repeat represses silencing in embryonic stem cells. J. Biol. Chem., 279: 34-41.
101. Sze, D.Y., Freeman, S.M., Slonim, S.M., Samuels, S.L., Andrews, J.C., Hicks, M., Ahrar, K., Gupta, S. and Reid, T.R. (2003) Dr. Gary J. Becker Young Investigator Award: intraarterial adenovirus for metastatic gastrointestinal cancer: activity, radiographic response, and survival. J. Vasc. Interv. Radiol., 14: 279-90.
102. Tai, C.K., Logg, C.R., Park, J.M., Anderson, W.F., Press, M.F. and Kasahara, N. (2003) Antibody-mediated targeting of replication-competent retroviral vectors. Hum. Gene Ther., 14: 789-802.
103. Tai, C.K., Wang, W., Chen, T.C. and Kasahara, N. (2005) Single-shot, multi-cycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma. Mol. Ther., in press, available online 13 May 2005.
104. Tamura, K., Tamura, M., Ikenaka, K., Yoshimatsu, T., Miyao, Y., Nanmoku, K. and Shimizu, K. (2001) Eradication of murine brain tumors by direct inoculation of concentrated high titer-recombinant retrovirus harboring the herpes simplex virus thymidine kinase gene. Gene Ther., 8: 215-22.
105. Thorne, S.H., Hwang, T.H. and Kirn, D.H. (2005) Vaccinia virus and oncolytic virotherapy of cancer. Curr. Opin. Mol. Ther., 7: 359-65.
106. Toda, M., Rabkin, S.D., Kojima, H. and Martuza, R.L. (1999) Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum. Gene Ther., 10: 385-93.
107. Toyoda, H., Ido, M., Hayashi, T., Gabazza, E.C., Suzuki, K., Kisenge, R.R., Kang, J., Hori, H. and Komada, Y. (2004) Experimental treatment of human neuroblastoma using live-attenuated poliovirus. Int. J. Oncol., 24: 49-58.
108. Traister, R.S. and Lynch, W.P. (2002) Reexamination of amphotropic murine leukemia virus neurovirulence: neural stem cell-mediated microglial infection fails to induce acute neurodegeneration. Virology, 293: 262-72.
109. Trajcevski, S., Solly, S.K., Frisen, C., Trenado, A., Cosset, F.L. and Klatzmann, D. (2005) Characterization of a semi-replicative gene delivery system allowing propagation of complementary defective retroviral vectors. J. Gene Med., 7: 276-87.
110. Unno, Y., Shino, Y., Kondo, F., Igarashi, N., Wang, G., Shimura, R., Yamaguchi, T., Asano, T., Saisho, H., Sekiya, S. and Shirasawa, H. (2005) Oncolytic viral therapy for cervical and ovarian cancer cells by Sindbis virus AR339 strain. Clin. Cancer Res., 11: 4553-60.
111. Varghese, S. and Rabkin, S.D. (2002) Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther., 9: 967-78.
112. Walker, J.R., McGeagh, K.G., Sundaresan, P., Jorgensen, T.J., Rabkin, S.D. and Martuza, R.L. (1999) Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum. Gene Ther., 10: 2237-43.
113. Wang, W., Tai, C.K., Kasahara, N. and Chen, T.C. (2003) Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retrovirus vectors. Hum. Gene Ther., 14: 117-27.
114. Weber, E., Anderson, W.F. and Kasahara, N. (2001) Recent advances in retrovirus vector-mediated gene therapy: teaching an old vector new tricks. Curr. Opin. Mol. Ther., 3: 439-53.
115. Wollmann, G., Tattersall, P. and van den Pol, A.N. (2005) Targeting human glioblastoma cells: comparison of nine viruses with oncolytic potential. J. Virol., 79: 6005-22.
116. Xia, Z.J., Chang, J.H., Zhang, L., Jiang, W.Q., Guan, Z.Z., Liu, J.W., Zhang, Y., Hu, X.H., Wu, G.H., Wang, H.Q., Chen, Z.C., Chen, J.C., Zhou, Q.H., Lu, J.W., Fan, Q.X., Huang, J.J. and Zheng, X. (2004) [Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus.]. Ai Zheng, 23: 1666-70.
117. Yamaki, T., Uede, T. and Kikuchi, K. (1990) Cellular mechanisms of tumor rejection in rats. Nat. Immun. Cell Growth Regul., 9: 1-25.
118. Yang, W.Q., Senger, D.L., Lun, X.Q., Muzik, H., Shi, Z.Q., Dyck, R.H., Norman, K., Brasher, P.M., Rewcastle, N.B., George, D., Stewart, D., Lee, P.W. and Forsyth, P.A. (2004) Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer. Gene Ther., 11: 1579-89.
119. Yang, Y., Jooss, K.U., Su, Q., Ertl, H.C. and Wilson, J.M. (1996a) Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther., 3: 137-44.
120. Yang, Y., Su, Q. and Wilson, J.M. (1996b) Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. J. Virol., 70: 7209-12.
121. Yao, S., Osborne, C.S., Bharadwaj, R.R., Pasceri, P., Sukonnik, T., Pannell, D., Recillas-Targa, F., West, A.G. and Ellis, J. (2003) Retrovirus silencer blocking by the cHS4 insulator is CTCF independent. Nucl. Acid Res., 31: 5317-23.
122. Yoon, T.K., Shichinohe, T., Laquerre, S. and Kasahara, N. (2001) Selectively replicating adenoviruses for oncolytic therapy. Curr. Cancer Drug Targets, 1: 85-107.
123. Zeh, H.J. and Bartlett, D.L. (2002) Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers. Cancer Gene Ther., 9: 1001-12.